1. Tirzepatide has earned the informal designation "twincretin." Which property of the molecule justifies this term?
A) It is a single peptide that acts as an agonist at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R)
B) It is a fixed-dose physical combination of two separate peptides, one selective for GIPR and one selective for GLP-1R
C) It activates the GLP-1R but blocks the GIPR, producing a net incretin-sparing effect
D) It is a GLP-1R agonist that is co-formulated with metformin to provide two mechanisms of glucose lowering
E) It agonizes the glucagon receptor (GCGR) in addition to the GLP-1R, combining two counter-regulatory pathways
ANSWER: A
Rationale:
Tirzepatide is a single 39-amino-acid peptide engineered to act as a balanced agonist at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Because it engages the two incretin receptors with one molecule, it is informally called a "twincretin," distinguishing it from selective GLP-1R agonists such as semaglutide that have no intrinsic GIPR activity.
Option B: Option B is incorrect because tirzepatide is one peptide, not a physical combination of two separate selective peptides.
Option C: Option C is incorrect because tirzepatide agonizes the GIPR rather than blocking it; there is no incretin-sparing antagonism.
Option D: Option D is incorrect because the twincretin term refers to dual incretin-receptor agonism within a single peptide, not co-formulation with metformin.
Option E: Option E is incorrect because tirzepatide does not agonize the glucagon receptor (GCGR); triple agonism that adds GCGR activity describes the investigational agent retatrutide, not tirzepatide.
2. Tirzepatide is administered once weekly by subcutaneous injection. Which structural feature is most directly responsible for its prolonged half-life of approximately five days?
A) A glycosylation pattern that prevents renal filtration of the intact peptide
B) A fatty diacid moiety attached through a linker that promotes binding to circulating albumin
C) Encapsulation in a lipid nanoparticle that releases the peptide slowly from the injection site
D) Substitution of all native amino acids with D-isomers that resist all peptidase cleavage
E) Covalent conjugation to an immunoglobulin Fc fragment that engages neonatal Fc receptor recycling
ANSWER: B
Rationale:
Tirzepatide incorporates a fatty diacid moiety attached via a linker to lysine at position 26. This lipid side chain binds reversibly to circulating albumin, which slows renal clearance and proteolysis and extends the half-life to approximately five days, permitting once-weekly subcutaneous dosing.
Option A: Option A is incorrect because the prolonged half-life derives from albumin binding through the fatty diacid, not from a glycosylation pattern blocking renal filtration.
Option C: Option C is incorrect because tirzepatide is a soluble peptide solution, not a lipid-nanoparticle depot formulation.
Option D: Option D is incorrect because tirzepatide is not built entirely from D-isomer amino acids; its durability comes principally from albumin binding rather than wholesale stereochemical inversion.
Option E: Option E is incorrect because tirzepatide is not an Fc-fusion protein; it does not rely on neonatal Fc receptor recycling, which is the mechanism used by certain antibody-based therapeutics rather than this incretin peptide.
3. A key feature of glucagon-like peptide-1 receptor (GLP-1R) agonism that limits its intrinsic hypoglycemia risk is that the insulin secretion it stimulates is:
A) Independent of plasma glucose, producing a fixed insulin output regardless of blood sugar
B) Driven primarily by direct alpha-cell stimulation rather than beta-cell signaling
C) Glucose-dependent, occurring chiefly when plasma glucose is elevated and diminishing as glucose normalizes
D) Mediated by inhibition of hepatic gluconeogenesis with no direct effect on the pancreatic islet
E) Produced only after conversion of the drug to an active metabolite in the liver
ANSWER: C
Rationale:
GLP-1R agonism stimulates insulin secretion in a glucose-dependent manner: the insulinotropic effect is most pronounced when plasma glucose is elevated and wanes as glucose returns toward normal. This glucose dependence is the central reason GLP-1R agonists carry low intrinsic hypoglycemia risk when used without insulin or a sulfonylurea.
Option A: Option A is incorrect because the effect is glucose-dependent rather than fixed and glucose-independent; a fixed insulin output would substantially raise hypoglycemia risk.
Option B: Option B is incorrect because the insulinotropic action is exerted on the pancreatic beta cell; GLP-1R agonism suppresses glucagon from alpha cells rather than stimulating them to drive insulin release.
Option D: Option D is incorrect because GLP-1R agonism acts directly on the islet to promote glucose-dependent insulin secretion and to suppress glucagon, not solely by inhibiting hepatic gluconeogenesis.
Option E: Option E is incorrect because tirzepatide and other incretin agonists act directly at the receptor and do not require hepatic conversion to an active metabolite.
4. The tirzepatide clinical program is divided into two major trial families, SURPASS and SURMOUNT. Which statement correctly distinguishes them?
A) SURPASS enrolled patients with obesity and a primary weight endpoint; SURMOUNT enrolled patients with type 2 diabetes and a primary glycated hemoglobin (HbA1c) endpoint
B) Both families enrolled only patients with established atherosclerotic cardiovascular disease and shared a primary three-point major adverse cardiovascular event endpoint
C) SURPASS evaluated oral tirzepatide and SURMOUNT evaluated injectable tirzepatide, with identical patient populations
D) SURPASS enrolled patients with type 2 diabetes with a primary glycated hemoglobin (HbA1c) endpoint; SURMOUNT enrolled patients with obesity with a primary body weight endpoint
E) SURPASS tested tirzepatide against placebo only, whereas SURMOUNT tested it only against bariatric surgery
ANSWER: D
Rationale:
The SURPASS program comprised phase 3 trials in type 2 diabetes mellitus (T2DM) with glycated hemoglobin (HbA1c) reduction as the primary endpoint, while the SURMOUNT program studied tirzepatide for obesity with body weight reduction as the primary endpoint (SURMOUNT-1 in patients without T2DM, SURMOUNT-2 in patients with T2DM).
Option A: Option A is incorrect because it reverses the two programs, assigning the obesity/weight design to SURPASS and the diabetes/HbA1c design to SURMOUNT.
Option B: Option B is incorrect because routine SURPASS and SURMOUNT trials did not all require established cardiovascular disease or share a major adverse cardiovascular event endpoint; that design describes the separate SURPASS-CVOT trial.
Option C: Option C is incorrect because both programs evaluated injectable subcutaneous tirzepatide and enrolled different populations, not identical ones.
Option E: Option E is incorrect because the comparators varied and included placebo, semaglutide, and insulin rather than bariatric surgery; SURMOUNT did not test tirzepatide against surgery.
5. Within the hypothalamic arcuate nucleus (ARC), neurons that co-express neuropeptide Y (NPY) and agouti-related peptide (AgRP) exert which effect on energy balance?
A) They are anorexigenic, suppressing food intake by releasing alpha-melanocyte-stimulating hormone
B) They are metabolically silent and serve only as structural scaffolding for POMC neurons
C) They sense circulating insulin exclusively and have no role in appetite regulation
D) They release glucagon-like peptide-1 into the systemic circulation to slow gastric emptying
E) They are orexigenic, promoting food intake when activated
ANSWER: E
Rationale:
Arcuate nucleus (ARC) neurons co-expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) are orexigenic: when activated they promote food intake, both by releasing NPY to stimulate feeding and by releasing AgRP, which blocks anorexigenic melanocortin signaling.
Option A: Option A is incorrect because release of alpha-melanocyte-stimulating hormone and appetite suppression are properties of pro-opiomelanocortin (POMC) neurons, the antagonistic population, not of NPY/AgRP neurons.
Option B: Option B is incorrect because NPY/AgRP neurons are functionally active drivers of appetite rather than inert scaffolding.
Option C: Option C is incorrect because these neurons integrate multiple signals and actively regulate appetite rather than merely sensing insulin with no behavioral role.
Option D: Option D is incorrect because glucagon-like peptide-1 is secreted chiefly by intestinal L cells and acts on GLP-1 receptors; ARC NPY/AgRP neurons do not release GLP-1 into the systemic circulation.
6. When pro-opiomelanocortin (POMC) neurons in the arcuate nucleus are activated, which sequence describes how they reduce food intake?
A) They release alpha-melanocyte-stimulating hormone (alpha-MSH), which binds the melanocortin 4 receptor (MC4R) to suppress appetite and increase energy expenditure
B) They release neuropeptide Y, which binds the melanocortin 4 receptor (MC4R) to stimulate feeding
C) They secrete agouti-related peptide, which acts as a full agonist at the melanocortin 4 receptor (MC4R) to suppress hunger
D) They release insulin directly into the paraventricular nucleus to inhibit feeding centers
E) They inhibit the nucleus tractus solitarius, thereby blocking vagal satiety signals
ANSWER: A
Rationale:
Activated pro-opiomelanocortin (POMC) neurons release alpha-melanocyte-stimulating hormone (alpha-MSH), which binds the melanocortin 4 receptor (MC4R) in the paraventricular nucleus and lateral hypothalamus to reduce food intake and increase energy expenditure.
Option B: Option B is incorrect because neuropeptide Y is an orexigenic transmitter of NPY/AgRP neurons and stimulates feeding rather than being released by POMC neurons.
Option C: Option C is incorrect because agouti-related peptide is an inverse agonist at the MC4R that blocks the anorexigenic signal; it is not a full agonist and is released by NPY/AgRP neurons, not POMC neurons.
Option D: Option D is incorrect because POMC neurons act through alpha-MSH and MC4R signaling rather than by releasing insulin into the paraventricular nucleus.
Option E: Option E is incorrect because the satiety pathway is reinforced, not blocked: GLP-1R signaling in the nucleus tractus solitarius amplifies vagal satiety signals rather than being inhibited by POMC neurons.
7. Among emerging incretin-based agents, retatrutide is best classified as which of the following?
A) A selective glucagon-like peptide-1 receptor (GLP-1R) agonist with no other receptor activity
B) A pure amylin receptor agonist co-administered with insulin
C) A triple agonist at the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR)
D) An oral small-molecule that antagonizes the glucagon receptor to lower hepatic glucose output
E) A sodium-glucose cotransporter-2 (SGLT-2) inhibitor repurposed for weight loss
ANSWER: C
Rationale:
Retatrutide is a single peptide that functions as a triple agonist at the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). The added GCGR agonism is intended to increase energy expenditure through hepatic fatty acid oxidation and brown adipose tissue thermogenesis.
Option A: Option A is incorrect because retatrutide engages three receptors, not the GLP-1R alone.
Option B: Option B is incorrect because amylin receptor agonism describes agents such as pramlintide and cagrilintide, not retatrutide.
Option D: Option D is incorrect because retatrutide agonizes the glucagon receptor as part of its mechanism and is an injectable peptide rather than an oral small-molecule glucagon-receptor antagonist.
Option E: Option E is incorrect because retatrutide is an incretin-based peptide triple agonist and is not an SGLT-2 inhibitor.
8. Tirzepatide shares the contraindications of the glucagon-like peptide-1 receptor (GLP-1R) agonist class. Which patient history represents a contraindication to its use?
A) A history of well-controlled essential hypertension on a single agent
B) A personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
C) A history of seasonal allergic rhinitis
D) A history of mild iron-deficiency anemia
E) A history of cholecystectomy performed five years earlier
ANSWER: B
Rationale:
Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), a class contraindication shared with GLP-1R agonists and based on rodent C-cell tumor findings.
Option A: Option A is incorrect because well-controlled hypertension is not a contraindication to tirzepatide.
Option C: Option C is incorrect because seasonal allergic rhinitis has no bearing on the safety of incretin therapy and is not a contraindication.
Option D: Option D is incorrect because mild iron-deficiency anemia is unrelated to the MTC/MEN2 contraindication and does not preclude tirzepatide.
Option E: Option E is incorrect because a remote cholecystectomy is not a listed contraindication; although GLP-1-based therapy is associated with gallbladder-related events, prior cholecystectomy does not contraindicate the drug.
9. Cagrilintide, a component of the investigational CagriSema combination, is best described as which type of agent?
A) An oral non-peptide glucagon-like peptide-1 receptor (GLP-1R) agonist
B) A dual glucose-dependent insulinotropic polypeptide receptor (GIPR)/glucagon-like peptide-1 receptor (GLP-1R) agonist identical to tirzepatide
C) A peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist
D) A long-acting amylin analog designed for once-weekly subcutaneous injection
E) A sulfonylurea that closes pancreatic ATP-sensitive potassium channels
ANSWER: D
Rationale:
Cagrilintide is a long-acting amylin analog engineered with a fatty acid chain for albumin binding, extending its half-life to roughly one week and allowing once-weekly subcutaneous dosing; it is paired with semaglutide in the CagriSema combination.
Option A: Option A is incorrect because oral non-peptide GLP-1R agonists describe agents such as orforglipron and danuglipron, not cagrilintide.
Option B: Option B is incorrect because cagrilintide is an amylin analog, not a GIPR/GLP-1R dual agonist; tirzepatide is the twincretin.
Option C: Option C is incorrect because PPAR-gamma agonism describes pioglitazone, an unrelated mechanism.
Option E: Option E is incorrect because cagrilintide is not a sulfonylurea and does not act on pancreatic ATP-sensitive potassium channels; it activates amylin receptors in the brainstem to reduce food intake.
10. Part of tirzepatide's weight-loss advantage over selective GLP-1R agonists is attributed to its glucose-dependent insulinotropic polypeptide receptor (GIPR) activity in adipose tissue. Which adipocyte effect best reflects this contribution?
A) GIPR agonism blocks all insulin signaling in adipocytes, forcing lipolysis and free fatty acid release
B) GIPR agonism converts white adipocytes into skeletal muscle fibers
C) GIPR agonism increases adipocyte insulin sensitivity and triglyceride uptake, lowering circulating free fatty acids and improving the metabolic milieu
D) GIPR agonism has no measurable effect on adipose tissue and acts only on pancreatic beta cells
E) GIPR agonism stimulates uncontrolled adipocyte proliferation, expanding fat mass
ANSWER: C
Rationale:
In the setting of concurrent GLP-1R activation, glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism in adipose tissue increases adipocyte insulin sensitivity and triglyceride uptake, which lowers circulating free fatty acids and improves the overall metabolic milieu in a way not achievable with GLP-1R agonism alone.
Option A: Option A is incorrect because GIPR agonism enhances rather than blocks adipocyte insulin signaling; it does not force lipolysis with free fatty acid release.
Option B: Option B is incorrect because GIPR agonism does not transdifferentiate white adipocytes into skeletal muscle.
Option D: Option D is incorrect because GIPR agonism does exert adipose-tissue effects and is not confined to the pancreatic beta cell.
Option E: Option E is incorrect because the adipocyte effect improves lipid handling rather than driving uncontrolled fat-cell proliferation and fat-mass expansion.
11. A patient who lost substantial weight on an incretin agonist regains much of it within a year of stopping the drug. Which mechanism best explains this rebound?
A) Discontinuation removes the pharmacological override of the hypothalamic weight set point, unmasking the orexigenic rebound that defends the previous body weight
B) The drug permanently lowered the body weight set point, so any regain reflects dietary indiscretion alone
C) Stopping the drug triggers irreversible destruction of pro-opiomelanocortin (POMC) neurons
D) Weight regain occurs because the drug had induced new brown adipose tissue that disappears instantly on cessation
E) Rebound reflects accumulation of the drug's active metabolite that paradoxically increases appetite after withdrawal
ANSWER: A
Rationale:
Body weight is defended around a hypothalamic set point; as weight falls, declining leptin and insulin increase orexigenic NPY/AgRP drive and reduce anorexigenic POMC signaling. Incretin agonism maintains weight loss by pharmacologically overriding this homeostatic resistance, so when the drug is stopped the override is removed and the orexigenic rebound is unmasked, returning weight toward the defended set point.
Option B: Option B is incorrect because the agents override rather than permanently reset the set point; regain is a predicted physiological response, not merely dietary indiscretion.
Option C: Option C is incorrect because discontinuation does not irreversibly destroy POMC neurons; the circuitry remains intact and resumes its prior balance.
Option D: Option D is incorrect because rebound is driven by restored orexigenic drive at the set point rather than by instant disappearance of newly induced brown adipose tissue.
Option E: Option E is incorrect because the rebound results from loss of the pharmacological override, not from an appetite-increasing active metabolite accumulating after withdrawal.
12. Adding glucagon receptor (GCGR) agonism to a GLP-1/GIP backbone, as in retatrutide, is intended to amplify weight loss through which mechanism?
A) Slowing of gastric emptying to near-complete gastric stasis
B) Direct inhibition of intestinal glucose absorption at the brush border
C) Blockade of the melanocortin 4 receptor to reduce energy storage
D) Promotion of renal glucose excretion through the proximal tubule
E) Increased energy expenditure via hepatic fatty acid oxidation and brown adipose tissue thermogenesis through uncoupling protein-1 (UCP-1)
ANSWER: E
Rationale:
Glucagon receptor (GCGR) agonism raises energy expenditure by upregulating hepatic fatty acid oxidation and by increasing thermogenic uncoupling protein-1 (UCP-1) expression in brown adipose tissue, thereby adding an energy-expenditure component to the appetite-suppressing actions of GLP-1R and GIPR agonism.
Option A: Option A is incorrect because the GCGR contribution is metabolic energy expenditure, not gastric stasis; excessive gastric stasis would be an adverse effect rather than the intended mechanism.
Option B: Option B is incorrect because GCGR agonism does not act by blocking intestinal brush-border glucose absorption.
Option C: Option C is incorrect because melanocortin 4 receptor blockade would be orexigenic and counterproductive; GCGR agonism does not work this way.
Option D: Option D is incorrect because promoting renal glucose excretion describes SGLT-2 inhibition, not glucagon receptor agonism.
13. Orforglipron, an oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist, differs pharmaceutically from oral semaglutide in which important way?
A) Orforglipron must be injected subcutaneously despite being called an oral agent
B) Orforglipron achieves oral bioavailability through conventional small-molecule absorption and does not require an absorption enhancer such as sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC)
C) Orforglipron is a peptide that, like oral semaglutide, must be coformulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) and taken fasting
D) Orforglipron is an antagonist at the GLP-1R rather than an agonist
E) Orforglipron must be administered with high-fat meals to be absorbed
ANSWER: B
Rationale:
Orforglipron is a non-peptide small-molecule GLP-1R agonist whose oral bioavailability arises from conventional small-molecule absorption in the small intestine, so it does not require the permeation enhancer sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) or the strict fasting administration needed for oral semaglutide, which is a peptide.
Option A: Option A is incorrect because orforglipron is genuinely an oral tablet, not a covertly injectable agent.
Option C: Option C is incorrect because orforglipron is a small molecule and does not need SNAC coformulation; that requirement belongs to peptide-based oral semaglutide.
Option D: Option D is incorrect because orforglipron is an agonist at the GLP-1R, not an antagonist.
Option E: Option E is incorrect because its absorption does not depend on administration with high-fat meals.
14. SURPASS-CVOT compared tirzepatide against dulaglutide rather than placebo in patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD). Why is the choice of an active comparator important for interpreting the result?
A) Because dulaglutide is a GLP-1R agonist with established cardiovascular benefit, demonstrating non-inferiority to it shows tirzepatide preserves the cardiovascular protection of the incretin class rather than merely beating placebo
B) Because dulaglutide has no cardiovascular effect, the comparison reveals nothing about tirzepatide's cardiovascular safety
C) Because the active comparator guarantees tirzepatide is superior to all other diabetes drugs in every endpoint
D) Because using an active comparator means the trial could not assess all-cause mortality
E) Because dulaglutide is a placebo formulation, the comparison is effectively against no treatment
ANSWER: A
Rationale:
Because dulaglutide is a GLP-1R agonist with proven cardiovascular benefit, showing that tirzepatide is non-inferior to it for the three-point major adverse cardiovascular event (MACE) composite indicates tirzepatide preserves the cardiovascular protection of the incretin class rather than simply outperforming an inert placebo.
Option B: Option B is incorrect because dulaglutide does have an established cardiovascular benefit, which is precisely what makes the active-comparator design informative.
Option C: Option C is incorrect because non-inferiority to one cardioprotective comparator does not establish superiority over all diabetes drugs in every endpoint.
Option D: Option D is incorrect because the active-comparator design did not preclude assessing all-cause mortality; the trial reported a reduction in all-cause mortality.
Option E: Option E is incorrect because dulaglutide is an active GLP-1R agonist, not a placebo formulation.
15. When tirzepatide is added to a patient already receiving basal insulin, what adjustment is typically recommended at initiation to reduce hypoglycemia risk?
A) Doubling the basal insulin dose to match the added glucose-lowering effect
B) Stopping all glucose monitoring because hypoglycemia no longer occurs
C) Switching the basal insulin to a thrice-daily rapid-acting analog
D) Reducing the basal insulin dose by approximately 20 percent, with further titration guided by fasting glucose
E) Adding a sulfonylurea to potentiate the insulin effect
ANSWER: D
Rationale:
When tirzepatide is combined with basal insulin, the basal insulin dose is typically reduced by about 20 percent at initiation to mitigate hypoglycemia risk, with subsequent titration guided by fasting glucose monitoring.
Option A: Option A is incorrect because doubling the insulin dose would compound the glucose-lowering effect and sharply increase hypoglycemia risk.
Option B: Option B is incorrect because glucose monitoring remains essential to guide titration; hypoglycemia risk is reduced but not eliminated.
Option C: Option C is incorrect because the recommended step is a dose reduction of basal insulin, not a switch to a thrice-daily rapid-acting analog.
Option E: Option E is incorrect because adding a sulfonylurea would increase hypoglycemia risk rather than reduce it and is the opposite of the intended adjustment.
16. Tirzepatide is started at 2.5 mg weekly and increased by 2.5 mg no more often than every four weeks. What is the principal rationale for this slow titration schedule?
A) To allow time for the kidneys to upregulate drug clearance pathways
B) To permit the development of neutralizing antibodies before reaching the target dose
C) To allow gastrointestinal accommodation and minimize nausea, vomiting, and diarrhea, the most common adverse effects and leading reasons for dose reduction
D) To prevent rapid bone loss associated with the drug
E) To delay the onset of glucose lowering until the maximum dose is reached
ANSWER: C
Rationale:
The slow four-week titration interval allows gastrointestinal accommodation and minimizes nausea, vomiting, and diarrhea, which are the most common adverse effects of tirzepatide and the primary reasons for dose reduction or discontinuation.
Option A: Option A is incorrect because the schedule is driven by gastrointestinal tolerability, not by a need for the kidneys to upregulate clearance pathways.
Option B: Option B is incorrect because slow titration is not intended to permit neutralizing-antibody development, which would be undesirable.
Option D: Option D is incorrect because bone loss is a concern associated with pioglitazone rather than a rationale for tirzepatide titration.
Option E: Option E is incorrect because glucose lowering begins at therapeutic doses during titration and is not intentionally delayed until the maximum dose is reached.
17. Two patients with obesity achieve comparable glucagon-like peptide-1 receptor (GLP-1R) activation, one from semaglutide and one from tirzepatide, yet the tirzepatide-treated patient loses more weight. Drawing on the receptor pharmacology covered earlier, which factor best accounts for the difference?
A) Tirzepatide is dosed daily whereas semaglutide is dosed weekly, giving more frequent exposure
B) Semaglutide blocks the glucose-dependent insulinotropic polypeptide receptor (GIPR), actively opposing weight loss
C) Tirzepatide is an oral agent and therefore better absorbed than injectable semaglutide
D) The two drugs produce identical central effects, so the difference is due to chance alone
E) Tirzepatide adds central glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism, which contributes independently to appetite suppression beyond GLP-1R activation
ANSWER: E
Rationale:
At comparable GLP-1R activation, tirzepatide's additional central glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism contributes independently to appetite suppression, which is the most pharmacologically compelling explanation for its weight-loss superiority over semaglutide.
Option A: Option A is incorrect because both tirzepatide and semaglutide are once-weekly injectables in this comparison, so dosing frequency does not explain the difference.
Option B: Option B is incorrect because semaglutide is GIPR-inactive, not a GIPR blocker; it neither activates nor antagonizes that receptor.
Option C: Option C is incorrect because the tirzepatide compared here is the injectable peptide, not an oral agent with superior absorption.
Option D: Option D is incorrect because the drugs do not produce identical central effects; the added GIPR contribution is a defined mechanistic difference rather than chance.
18. Building on the melanocortin circuitry described earlier, how does agouti-related peptide (AgRP) promote feeding in a manner distinct from neuropeptide Y (NPY)?
A) AgRP acts as an inverse agonist at the melanocortin 4 receptor (MC4R), blocking the anorexigenic alpha-melanocyte-stimulating hormone signal, whereas NPY directly stimulates feeding through its own receptors
B) AgRP and NPY are the same molecule released under different names, with no mechanistic difference
C) AgRP binds the melanocortin 4 receptor (MC4R) as a full agonist to suppress appetite
D) AgRP stimulates pro-opiomelanocortin (POMC) neurons to release more alpha-melanocyte-stimulating hormone
E) AgRP acts only in the brainstem nucleus tractus solitarius and has no hypothalamic action
ANSWER: A
Rationale:
Agouti-related peptide (AgRP) is an inverse agonist at the melanocortin 4 receptor (MC4R): it blocks the anorexigenic signal from pro-opiomelanocortin (POMC)-derived alpha-melanocyte-stimulating hormone, while neuropeptide Y (NPY) promotes feeding directly through its own receptors. The two co-released peptides thus promote feeding by complementary but distinct mechanisms.
Option B: Option B is incorrect because AgRP and NPY are distinct peptides with different molecular actions, though co-expressed in the same neurons.
Option C: Option C is incorrect because AgRP is an inverse agonist that blocks MC4R signaling, not a full agonist that suppresses appetite.
Option D: Option D is incorrect because AgRP opposes melanocortin signaling rather than stimulating POMC neurons to release more alpha-melanocyte-stimulating hormone.
Option E: Option E is incorrect because AgRP acts within the hypothalamic melanocortin circuitry at the MC4R rather than being confined to the brainstem nucleus tractus solitarius.
19. In obesity-related heart failure with preserved ejection fraction (HFpEF), how did the SUMMIT trial of tirzepatide differ in outcome from the STEP-HFpEF trial of semaglutide?
A) Neither trial showed any benefit on symptoms or events in HFpEF
B) SUMMIT showed a significant reduction in the composite of cardiovascular death or worsening heart failure events, whereas STEP-HFpEF improved symptom and functional measures without a significant reduction in that combined event endpoint
C) STEP-HFpEF reduced cardiovascular death or worsening heart failure events, whereas SUMMIT showed no symptom benefit
D) Both trials demonstrated identical reductions in the combined cardiovascular event endpoint
E) SUMMIT enrolled only lean patients without obesity, making the trials incomparable
ANSWER: B
Rationale:
In obesity-related HFpEF, SUMMIT (tirzepatide) demonstrated a significant reduction in the composite of cardiovascular death or worsening heart failure events, while STEP-HFpEF (semaglutide) improved symptom burden and functional measures such as the Kansas City Cardiomyopathy Questionnaire score and walking distance without a significant reduction in that combined event endpoint.
Option A: Option A is incorrect because both trials showed benefit; STEP-HFpEF improved symptoms and SUMMIT additionally reduced the event composite.
Option C: Option C is incorrect because it reverses the findings, attributing the event reduction to STEP-HFpEF and denying SUMMIT any symptom benefit.
Option D: Option D is incorrect because the two trials did not show identical reductions in the combined event endpoint; only SUMMIT achieved a significant reduction in that composite.
Option E: Option E is incorrect because SUMMIT enrolled patients with HFpEF and obesity (body mass index 30 or greater), not lean patients.
20. A patient with type 2 diabetes and biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) needs pharmacological therapy with hepatic benefit. Applying the comparison discussed earlier, why might tirzepatide be preferred over pioglitazone?
A) Pioglitazone has never shown any histological benefit in steatohepatitis, so it is not a real comparator
B) Tirzepatide cures cirrhosis outright, whereas pioglitazone cannot
C) Tirzepatide provides glycemic control, weight reduction, and direct hepatic benefit, whereas pioglitazone promotes weight gain, fluid retention, and bone loss
D) Pioglitazone is contraindicated in all patients with type 2 diabetes
E) Tirzepatide is an oral peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with the same mechanism as pioglitazone but fewer effects
ANSWER: C
Rationale:
For a patient with type 2 diabetes and MASH, tirzepatide combines glycemic control, substantial weight reduction, and direct hepatic benefit, whereas pioglitazone—although it has demonstrated histological efficacy in MASH—promotes weight gain, fluid retention, and bone loss, making tirzepatide the more favorable option in this setting.
Option A: Option A is incorrect because pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist, does have demonstrated histological benefit in steatohepatitis and is a legitimate comparator.
Option B: Option B is incorrect because tirzepatide does not outright cure cirrhosis; the comparison concerns MASH resolution and tolerability, not reversal of established cirrhosis.
Option D: Option D is incorrect because pioglitazone is not contraindicated in all type 2 diabetes patients; its use is limited by specific adverse effects rather than a blanket contraindication.
Option E: Option E is incorrect because tirzepatide is an injectable GIP/GLP-1 dual agonist, not an oral PPAR-gamma agonist sharing pioglitazone's mechanism.
21. A prescriber is reviewing a patient's regimen that includes tirzepatide. Which proposed combination should be avoided because the mechanisms overlap without providing additive benefit?
A) Tirzepatide with appropriately dose-reduced basal insulin
B) Tirzepatide with metformin
C) Tirzepatide with a statin for lipid management
D) Tirzepatide together with another glucagon-like peptide-1 receptor (GLP-1R) agonist or with pramlintide
E) Tirzepatide with an antihypertensive agent
ANSWER: D
Rationale:
Tirzepatide should not be combined with another glucagon-like peptide-1 receptor (GLP-1R) agonist or with pramlintide, because the overlapping incretin and amylin-related mechanisms provide no additive benefit and increase adverse-effect risk.
Option A: Option A is incorrect because tirzepatide can be combined with basal insulin when the insulin dose is appropriately reduced (about 20 percent) at initiation, as covered earlier.
Option B: Option B is incorrect because tirzepatide is commonly and appropriately used with metformin, including in the trial programs.
Option C: Option C is incorrect because a statin addresses lipids through an unrelated mechanism and is not a problematic overlap with tirzepatide.
Option E: Option E is incorrect because antihypertensive therapy targets a different pathway and is not the overlapping combination to avoid.
22. Beyond the arcuate nucleus circuitry, glucagon-like peptide-1 receptor (GLP-1R) agonism also acts in the brainstem. Applying the satiety physiology described earlier, what is the effect of GLP-1R agonism in the nucleus tractus solitarius (NTS)?
A) It stimulates the orexigenic NPY/AgRP neurons of the arcuate nucleus to increase food intake
B) It blocks vagal afferent transmission, abolishing the sensation of fullness
C) It amplifies vagal satiety signals relayed from the gut, reducing meal size independently of the hypothalamic arcuate circuit
D) It directly stimulates pancreatic beta cells to release insulin from within the brainstem
E) It converts the NTS into the primary site of triglyceride storage
ANSWER: C
Rationale:
The nucleus tractus solitarius (NTS) receives vagal afferent signals from gut mechanoreceptors and chemoreceptors; GLP-1R agonism at NTS neurons amplifies these vagal satiety signals, reducing meal size and frequency independently of the hypothalamic arcuate circuit.
Option A: Option A is incorrect because GLP-1R agonism suppresses, rather than stimulates, orexigenic NPY/AgRP drive and reduces food intake.
Option B: Option B is incorrect because GLP-1R agonism enhances vagal satiety signaling rather than blocking vagal afferent transmission and abolishing fullness.
Option D: Option D is incorrect because the NTS effect relays satiety information centrally rather than directly stimulating pancreatic beta cells to secrete insulin from within the brainstem.
Option E: Option E is incorrect because the NTS is a satiety-relay nucleus, not a site of triglyceride storage.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.